No Data
No Data
Zelgen Biopharma Gets Nod to Trial Small Cell Cancer Drug Combination; Shares Up 5%
Zelgen Biopharmaceuticals' Loss Narrows in 2024; Shares Up 5%
Zejing Pharmaceutical\'s 2025 First Quarter Report
Zejing Pharmaceutical 2024 Annual Report
Summary of the 2024 Annual Report of Zejing Pharmaceutical
Zhongjing Pharmaceutical (688266.SH) released its 2024 annual performance, with a net loss attributable to shareholders of 0.138 billion yuan, a narrowing of losses.
Zhejiang ZJ Pharmaceuticals (688266.SH) released its annual report for 2024, with revenue for the year reaching 5....